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The wide use of bound enzyme coils with hexokinase and
glucose-6-phosphate dehydrogenase in automated analysis for
serum-glucose assay [1, 2-] demonstrates the potential of open
tubular heterogeneous enzyme reactors [3] in clinical analysis.
Such reactors have also been prepared with other enzymes I-4, 5]
and in this paper the authors describe a continuous-flow method
for uric acid assay with immobilized uricase, as well as some of
the characteristics of bound uricase coils.
The classic alkaline phosphotungstate method for uric acid
assay has been gradually replaced by enzymic methods that
employ uricase and measure the concentration of one of the
reaction products: allantoin or hydrogen peroxide [6-12]. The
authors used tubes with immobilized uricase at the inner wall on
Technicon’s SMA and SMAC continuous-flow analysers and
the reaction scheme is shown in figure 1. Dialysed uric acid
enters the reactor coil and is oxidized in a reaction catalysed by
l_xy..
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Figure 1. Schematic illustration of ureate oxidation by
uricase immobilized at the tube wall and the subsequent
indicator reactionfor hydrogen peroxide that takes place in
the liquid phase.
immobilized uricase. The concentration of hydrogen peroxide
formed in the reaction is measured by the indicator reaction that
involves the oxidative coupling of 3 methyl-2-benzothiazolinone
hydrazone (MBTH) and anthranilic acid in the presence of
peroxidase. The uric acid concentration is proportional to that
of the blue indamine dye, which is measured colorimetrically at
570nm.
Materials and methods
Reagents and standards
The sample diluent used was Technicon’s T01-0992, which
contains g of ethylene-diaminetetraacetic acid (EDTA)
disodium salt and 0"8g EDTA ferric sodium salt (Technicon)
dissolved in 11 of phosphate buffer. The pH of the diluent was
7.3. The borate buffer was T01-0988, 0"5 mol/1 at pH 9"2. For the
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colour reagent the contents of a vial of T01-1085 or Tll-0989
colour reagent for uric acid (Technicon) was dissolved in 200 ml
of water to make solutions for use on an SMAC and an SMA
12/60, respectively. Both reagents contain 3.06 g of anthranilic
acid and 0.10 g MBTH/1. Peroxidase reagent was prepared by
reconstituting a vial of lyophilized horse-radish peroxidase
(T11-0579) with 200 ml ofperoxidase reagent diluent (T21-0582)
in order to obtain a solution with 16kU ofperoxidase activity/1.
To prepare the uric acid standard (1.0 g/l) 100mg ofuric acid
(MBS reference reagent) and 100rag of lithium carbonate was
dissolved in 100ml of distilled water. This stock solution is
stable for about one month if refrigerated and protected from
light. Working uric acid standards are prepared by diluting the
stock solution to give 2, 4, 6, 8, 10, 12 and 15mg of uric acid/dl.
The bound uricase coil was made by coating polyamide
tubing with uricase from Candida utilis, according to the
procedure described by Hdrvath and Solomon [13]. The inner
diameters and lengths of the bound enzyme tubes were 0"10and
25 cm for the SMAC and 0" 16 and 30 cm for the SMA. The tubes
were coiled and mounted into 6mm I.D. plastic sheath with
proper connections to the appropriate SMA and SMAC
cartridges.
Serum samples: pooled human serum was obtained from the
Memorial Sloan-Kettering Medical Center (New York, N.Y..
10021) and stored at -18C. The reference serum used was
manufactured by Technicon.
Instrumentation and procedures
Custom-built single-channel SMAC and SMA analysers were
used for method development. A simplified flow-sheet, ap-
propriate for both kinds of cartridges together with pertinent
operational details, is shown in figure 2. Method performance
characteristics were subsequently evaluated on the SMAC and
SMA instruments generally used in clinical laboratories.
Evaluation of carry-over
A set of nine samples, six of which had low uric acid concent-
rations and three high concentrations, was analysed in the order
shown by the tracing in figure 5. The ratio .of uric acid
concentrations for the ’high’ and ’low’ samples was 10.
Percentage sample interaction, C.O., was calculated by using the
formula
C.O.= IO0(AT--IL)/(I,--IL) (1)
where A7 is the absorbance at the flat of the tracing for sample
No. 7, AL is the average absorbance for sample Nos. 2, 3, 8 and 9
whereas An is the average reading for sample Nos. 5 and 6.
Results and discussion
Evaluation of the method
The studies were carried out with three different SMA 12/60
units and three different SMAC instruments, over 10 consecu-
tive working days, in order to characterize the performance of
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the new method under field conditions at three laboratories: Mt.
Sinai Hospital (Baltimore, Maryland 21215); Lakeville Medical
Labs (New York, N.Y. 10021); and Technicon’s Reference and
Evaluation Laboratory. In-house evaluation was based on a
specially designed computerized protocol [14], which yields
detailed information on precision, percentage recovery, ac-
curacy, carry-over and drift on the analytical data obtained with
SMA 12/60s and SMACs. Three samples were prepared with
low, medium, and high uric acid concentrations by using human
serum pool oflow uric acid level as the diluent, and assayed. The
results are listed in tables and 2 and can be summarized as
follows.
Sensitivity
Themaximum sensitivity ofthis method with a fresh, 30cm long
immobilized-uricase coil was found to be 0"02 absorbance
units/mg/dl uric acid under conditions employed on SMAC
equipped with an 18 in. dialyser. A prolonged test for oper-
ational stability showed a slight decrease in coil activity after 20
days.
Range of linearity
Linear response was obtained with samples having uric acid
concentrations up to 12 and 15 mg/dl for SMA and SMAC,
respectively.
Drift
The average drift was found to correspond to a uric acid
concentration of +0.17mg/dl for both the SMA 12/60 and
SMAC within the usual recalibration cycle of 10 and 47
specimens, respectively.
Carry-over
In a broad concentration range with the three samples, carry-
over was found to be 4.8___0.57 and 1.0+0.24 for the SMAC
and SMA 12/60, respectively.
Correlation
Over 100 serum samples, each approximately one week old, were
randomly selected from a hospital population, and assayed in
duplicate for uric acid in a random sequence at a rate of 10
samples per day over a period of 10 days. The present method
with bound uricase coil was compared to both the manual
uricase method with spectrophotometry at 293nm and
continuous-flow methods with phosphotungstate on Technicon
analysers. Results of the statistical evaluation are in excellent
agreement with those obtained by the other assay procedures as
shown in table 3.
Interferences
Uric acid assay is generally subject to interference by certain
components. For instance, in the automated method devised by
Gochman and Schrnitz [9], ascorbic acid seriously depressed
colour development in the indicator reaction and similar
observations were made by Klose et al. [12]. The authors used
EDTA-iron complex [15] to counteract such interference. As
seen in table 4, when the concentration of ascorbic acid is not
higher than 5 mg/dl, interference is suppressed. Thus the use of
the metal complex is effective in alleviating interference by
ascorbic acid, the concentration ofwhich is expected to be much
lower than 5 mg/dl, and can minimize the effect ofother reducing
substances commonly found in serum.
Table 4 also shows the results obtained with a variety of
other substances potentially present in serum. Human serum
samples were spiked with the substances at concentrations
corresponding to multiple-interference levels, and serum devoid
of interfering substances was used as the reference. Allopurinol,
bilirubin, creatinine, cysteine, glucose, hypoxantine, phenol,
theophylline, triglycerides, heparin, salicylate, EDTA, oxalate
and iodoacetate showed no clinically significant bias on the
method at the upper limit oftheir expected serum concentration.
On the other hand, clinically significant interference by the
Table 1. Precision of uric acid assay with bound uricase coils on the SMA 12/60 and SMAC systems as evaluatedfrom
measurements with human serum pools having low, mid and high glucose concentrations.
Method Level
Mean uric acid Total Total Within-run Within-run
concentration precision precision precision precision
(mg/dl) (SD)’ (CV%) (S.D.) (CVo)
SMA Low 2-1 0.07 3"2 0"05 2"5
Mid 7.7 0.09 1"2 0’09 1’2
High 12"9 0’ 18 1"3 0" 11 0"9
SMAC Low 2.5 0"27 11"1 0"27 10"9
Mid 9.4 0.27 2"8 0"27 2’8
High 15.4 0.34 2"2 0’26 1.7
1. Includes day-to-day plus within-run precision data.
Table 2. Accuracy of uric acid assay with bound uricase coils on the SMA 12/60 and SMAC systems as evaluatedfrom
measurements with human serum pools having low, mid and high glucose concentration. Theoretical uric acid values were
obtained by measuring uric acid concentrations with the spectrophotometer at 293 nm.
Method Level
Theoretical Uric acid Deviation from
uric acid concentration expected uric acid Uric acid
concentration recovered concentration recovered
(mg/dl) (mg/dl) (mg/dl) (%)
SMA Low
Mid
High
2"1 2"0 -0’1 95.7
7"4 7.7 0"3 104.6
12"6 13.0 0.4 103.4
SMAC Low 2"4 2.1 -0’3 88"4
Mid 9’ 9"4 0’ 3 104’4
High 15" 8 15’7 -0" 99"6
12Table 3.
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Correlation between the present method with bound uricase coils and other methodsfor uric acid assay in serum.
Continuous flow
method with bound Reference
uricase coils methods
y X
Number of
assays
Standard
Regression Correlation error of
equation coefficient estimate
SMA 12/60 Manual with uricase 105
(spectrophotometer
at 293 nm)
SMA 12/60 SMA 12/60 with 291
phosphotungstate
SMAC SMA 12/60 with 342
bound uricase coil
SMAC SMA 12/60 with 343
phosphotungstate
y=0"993 x -0"0 0"997 0’2
y-- 1"031 x -0"5 0"991 0"3
y=0"978 x +0"2 0"999 0’21
y=0"973 x +0"1 0"999 0"21
substances listed in table 4 was found on both the SMA and
SMAC.
Characterization of bound uricase coils
It has been established that upon sequestering the enzyme the
observed kinetics ofreaction may be profoundly changed due to
microenvironmental effects and diffusional resistances for the
substrate and product molecules in the system. With open
tubular heterogeneous enzyme reactors with continuous-flow
analysers the peculiarities ofdiffusion and sample interaction, in
segmented flow have also to be considered [17]. The charac-
teristics and operational behaviour observed with bound uricase
coils are briefly described in the following.
Effect of substrate concentration
Steady-state rates ofuric acid were measured with bound uricase
tubes of different lengths at various substrate concentrations.
Using the SMA 12/60 instrument without the dialyser, uric acid
was fed to the coil continuously in the reagent stream and the
uric acid concentration was measured spectrophotometrically at
293 nm in both the feed and the effluent. Reaction rates were
calculated from feed concentration, flow rate and conversion
and normalized by the internal geometrical surface area of the
coils. Lineweaver-Burk plots ofthe data are depicted in figure 3,
which also shows plots ofrate data obtained with uricase in free
solution. In the latter case, the K,, value was found to be
1.4 x 10- mol/1, in agreement with Pitts and Priest’s data [18].
The difference observed between the kinetic behaviour ofbound
and free uricase is attributed to the relative slowness of radial
mass transfer in enzyme coils under investigation [17].
Although the quasi-linear plots of the enzyme coil data in figure
3 cannot be used to extract meaningful kinetic parameters, they
show the expected trend as far as the slopes and intercepts are
concerned. When the tube length is increased from 3 to 10cm the
value of the reciprocal ordinate intercept, which some workers
would consider the normalized ’apparent’ Vmax of the reaction,
decreases, while the ’apparent’ K,, value increases. These
observations support the theory that predicts that the effect of
diffusional resistances in the coil, which cause the observed
kinetics to depart from the inherent kinetics of the enzymic
reaction, become more pronounced with increasing tube length
l-3, 19].
Effect of coil length
When the overall rate of reaction is determined by the rate of
substrate diffusion to the enzymic wall, theory predicts that the
Reagents Flow rates
(ml/min.)
SMA SMAC
Air (0.32) (0.09) Dialyser
Sample
diluent (0.8) (0.166)
Sample (0.23) (0.3851)
Waste
Colorimeter
at 570 nm
Air
Recipient
diluent
(0.32)
Chromogen (0.16) (0.074)
Bound
Three-way uricase
valve coil
Peroxidase (0.16) (0.0.74)
Figure 2. General flow-diagram for uric acid assay with bound uricase coils on the SMA 12/60 and SMAC biochemical
analysers usin9 Type H membrane in 24 in. and 18 in. dialysers respectively.
13L. P. Ledn et al. Immobilized uricase for automated uric acid assay
10 crn
3 cm
160
E
. Free solution
,.0_. o
-8 -6 -4 -2 0 2 4 6 8 10 12
Reciprocal uric acid concentration (I X mol-
X 104
Figure 3. Linewear-Burk plot ofkinetic data obtained with uricase infree solution and with bound uricase coils ofdifferent
lengths. Experiments were carried out on the same 12/60 by using continuous feed of uricase solution in 0"05 mol/l borate
buffer, at pH9"2, at a segmented flow rate of l’2ml/min. The concentration change for uric acid was followed
spectrophotometrically at 293 nm. Human serum samples spiked with uric acid were used.
normalized reaction rate is linearly dependent onU 2/3, where L
is the tube length [13]. Results obtained with uric acid
concentration in the range from 15 to 53gmol/1 under .the
conditions stated in figure 3 have indeed given straight lines on
plots ofthe normalized reaction rate againstU 2/3. Since a linear
relationship was observed with all tubes longer than 2cm the
authors conclude that with bound uricase coils of practical
interest the overall reaction rate strongly affected by diffusional
effects and is not determined by the inherent kinetics of the
enzymic reaction.
The length dependence of conversion was also investigated
under usual operating conditions of the SMAC, by using a
human serum pool spiked with uric acid to obtain a substrate
concentration of 15 mg/dl; the results are shown in figure 4. As
seen, practically full conversion is obtained with SMAC coils
longer than 60cm. On the other hand, results of a similar study
with the SMA showed a somewhat weaker dependence of
conversion on the tube length; the conversion at any length was
about 10 lower than that shown in figure 4. For the uric acid
assay method on the SMAC and SMA 12/60 the length ofbound
uricase coils was selected as 25 and 30cm, respectively. Such
coils, which initially yield 90 and 80 conversion on the SMAC
and SMA 12/60, have been found to represent the best
compromise as far as sensitivity, sample interaction and the
general quality ofthe tracing are concerned, as shown in figure 5.
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Figure 4. Dependence ofuric acid conversion on the length
ofbound uricase coils under conditions used on the SMAC.Coil length (cm)
100
Carry-over I%)
6.1 0,21
5.3 0.26
4.7+/-0,
4.5 0,40
5.0 0,33
5.3 0.54
5.9 0.54
7.3 0.25
Figure 5. Illustration ofthe effect ofcoil length on tracing
quality obtained with bound uricase coil on a custom-built
single-channel SMAC. The samples were from human
serum pool and spiked with uric acid. Samples are numbered
from left to right for the calculation of carry-over by using
equation (1). Thus, sample Nos. 1, 2 and 3, low in uric acid
arefollowed by Nos. 4, 5 and 6, which are high in uric acid,
and by Nos. 7, 8 and 9 having low uric acid concentration.
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Effect offlow rate
As radial mass transfer in tubular enzymic wall reactors strongly
increases with the velocity of segmented flow, the observed
reaction rate in bound enzyme coils usually increases with flow
rate. On the other hand, sample interaction is expected to be a
complex function of the flow rate [17]. In practice, therefore,
optimum flow rate is established empirically so that a comprom-
ise is found between maximum analytical sensitivity and mi-
nimum sample interaction. The effect of flow rate is illustrated
by tracings in figure 6, which were obtained in uric acid assay by
bound uricase coil on the SMAC. They show optimum results at
0.6 ml/min. Similar conditions led to the use of a flow rate of
1.3 ml/min, with SMA 12’60 cartridges.
Effect ofpH
The pH activity profiles obtained with uricase in free solution
and with a 25 cm long bound uricase coil for SMAC are depicted
in figure 7. The data shown for the enzyme coil are average
values obtained at uric acid concentrations in the range from
2.2 to 17.5mg/dl. Figure 7 shows that the pH profile for the
immobilized enzyme is much broader than that obtained with
the enzyme in free solution. This observation can also be
explained by the diffusion controlled nature ofthe reaction in the
Table 4. Investigation ofinterference with uric acid assay by various substances which may be present in human serum. The
data were obtained by using bound uricase coils on SMA and SMAC analysers (Technicon).
Interfering substance Theoretical
uric acid Measured uric Change in uric acid
Concentration concentration acid concentration concentration
Name (mg/dl) (mg/dl) (mg/dl) (mg/dl) (%)
Acetaminophen 40 11"0 10.4 0.6 5.5
Dopac 2 9.8 9.0 -0.8 8.2
20 9.8 6.1 -3.7 37.8
L-Dopa 2 10.9 10"5 -0.4 3.7
5 10.9 9"9 1.0 9.2
20 11.0 8"3 -2.7 24.5
Gentisic acid 2.5 11.2 10"9 -0.3 2.7
5 11.2 10"7 -0.5 4-5
10 11"2 10.4 -0.8 7.1
Hemoglobin
(severe hemolysis)
6-Mercaptopurine
-Methyldopa
Xanthine
Sodium citrate
Sodium fluoride
Ascorbic acid
Acetaminophen
Dopac
L-Dopa
Gentisic acid
Hemoglobin
6-Mercaptopurine
e-Methyldopa
Xanthine
Sodium citrate
Sodium fluoride
Ascorbic acid
5.2 4"6 -0"6 11.5
25 9.8 9.1 0.7 7.1
200 9-7 8"0 1.7 17.5
10 9.8 8"9 -0"9 9.2
400 9.8 4.8 5"0 51.0
10 9.8 6"3 -3.5 35.7
300 9.8 1"0 8’ 8 89.8
1176 3.4 3"2 -0"2 5.9
1050 3.2 2"9 -0.3 9.4
5 4.8 5"0 0’2 1.4
5 11.0 10"8 -0"2 1.4
10 4.8 5.2 0"4 8.3
40 12.0 11.7 -0"3 2.5
2"5 16.0 14"2 1.7 10.6
20 16"0 9"0 7.0 42.7
2"5 12.6 12.7 0.1 0"8
5"0 12.6 12.7 0.1 0"8
20 12"6 12"1 -0"5 4.0
2"5 12.6 11.4 -0"8 6.3
5"0 12.6 10"2 -2"4 14.0
500 11.3 10.8 -0"5 4.4
25 16.1 15"9 -0"2 1.2
200 16.1 15.8 -0"3 1.9
25 16.0 15.7 -0.3 1.9
400 16.0 11.6 -4.4 27.5
300 15.9 10.0 5.9 37.1
182 4.9 3"9 1.0 20.4
1050 4.9 5.1 0"2 4"
3 11.8 11.6 -0.2 1.7
5 11.8 10.5 1.3 11.0
10 11.8 7"9 -3.9 33.1
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IIII
bound uricase tube, i.e. the slowness of diffusion has a rate-
equalizing effect on the overall reaction--in the pH range from
2.5 to 10"0 the observed rate changes very little. The linearity of
the method has been found to depend strongly on the pH,
however. Satisfactory analytical results changing the pH from
this value in either direction resulted not only in decreasing
linearity but also in a drop of sensitivity, and a deterioration of
hydraulics. These observations mandate the use of the bound
uricase coils at pH 9"2 in uric acid assay on both the SMAC and
SMA 12/60.
NO. No. Flow rate
(ml/min.)
0.642
2 0.563
3 0.482
4 0.385
5 0.287
Figure 6. Illustration of the effect offlow rate on tracin9
quality obtained with bound uricase coil on a custom-built
single-channel SMAC. The samples were from human
serum pool and spiked with uric acid.
1.0
0.8
0.6
0.4
0.2
I’
Uricose free in solutio
Bound uricose coil
7.0 7.5 8.0 8.5 9.0 9.5 10.0
pH
Figure 7. pH profiles for bound and free uricase.
Experiments were carried out on SMA 12/60 with samples
havin9 different uric acid concentrations. The data depicted
here represent average values.
Eect of temperature
The rate of uric acid oxidation by bound uricase coils was
practically unaffected by temperature in the range from 19 to
50C at sample concentrations up to 7.3mg/dl. At a sample
concentration of 12"5 mg/dl the rate increase was less than in
the important temperature interval from 19 to 37C. From the
Arrhenius plot of these data we have calculated an activation
energy of approximately 5 kcal/mol. This value is about half of
that usually associated with enzymic reactions and also suggests
that the overall rate of the reaction is strongly affected by
diffusion, the activation energy of which is in the order of
2"5 kcal. The above findings suggest that under usual conditions
the reaction can be conveniently carried out at room tempera-
ture and no thermostatting of the enzyme coil is necessary to
obtain reproducible results.
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Stabilio’ of bound uricase coils
Enzyme coils from four different production lots were tested for
operational stability on a two-channel SMA system during
routine analytical work. The coils were not removed from the
cartridges during the test period. Typical stability profile is
illustrated in figure 8. The data show that after analysing 10000
samples over a period of 35 days the initial activity of the coil
declined by 24o. As the drop of analytical sensitivity was not
accompanied by untoward changes in linearity and sample
interaction the enzyme coils are considered to be sufficiently
stable for use in continuous flow analysers.
E
Number of samples x I0- 0.3 1.5 3.0 4.5 6.0 7.5 9.0 10.5
0.2
0.1
0.0 ,I I,,
5 10 15 20 25 30 35
Ooys
4o
Figure 8. Operational longevity ofa typical bound uricase
coil on the SMA 12/60 under usual conditions. The coils
were not removedfrom the instrument durin9 the time period
shown.
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